Type 2 Diabetes Trial, Recruiting (NCT05801614)

Type 2 Diabetes Trial, Recruiting NCT05801614 Sponsor: Region Stockholm Condition: Type 2 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT05801614 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 2 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have a blood sugar control reading (called HbA1c) above a certain level, whether or not they are currently on medication for it
People who were diagnosed with type 2 diabetes less than 6 years ago
People with a body mass index (BMI) of 27 or higher (or 25 or higher for people of Asian background)

Who may not be able to join:

People whose body is not producing enough insulin on its own (insulin deficiency)
People whose blood sugar control reading (HbA1c) is at or above a very high level (12% or 108 mmol/mol)
People currently being treated with certain diabetes medications known as sulphonylureas or SGLT2 inhibitors
People who have had a heart attack in the past 6 months
People with severe or unstable heart failure
People with other serious conditions, including cancer, psychiatric disorders, eating disorders, severe depression, or substance abuse
People with any other health conditions that may affect their ability to take part in the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Neda Rajamand Ekberg, MD, PhD, Region Stockholm

Phone: +468-123 671 50

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05801614

Sponsor: Region Stockholm

Phase: Not Applicable

Status: Recruiting

Condition: Type 2 Diabetes

Trial contact: +468-123 671 50

More information: https://clinicaltrials.gov/study/NCT05801614

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have a blood sugar control reading (called HbA1c) above a certain level, whether or not they are currently on medication for it
People who were diagnosed with type 2 diabetes less than 6 years ago
People with a body mass index (BMI) of 27 or higher (or 25 or higher for people of Asian background)

Who may not be able to join:

People whose body is not producing enough insulin on its own (insulin deficiency)
People whose blood sugar control reading (HbA1c) is at or above a very high level (12% or 108 mmol/mol)
People currently being treated with certain diabetes medications known as sulphonylureas or SGLT2 inhibitors
People who have had a heart attack in the past 6 months
People with severe or unstable heart failure
People with other serious conditions, including cancer, psychiatric disorders, eating disorders, severe depression, or substance abuse
People with any other health conditions that may affect their ability to take part in the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Region Stockholm

Registry

ClinicalTrials.gov

Start date

28 February 2022

Est. completion

28 February 2027

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

non-diabetic HbA1c; non diabetic HbA1c

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov